Actualizar mis citas con la selección
Presentar
resultados
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, et al..
Renin–angiotensin–aldosterone system inhibitors and risk of covid-19.
N Engl J Med 2020;382:18 de junio. [Ref.ID 103604]
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB.
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
Lancet 2019;394:24 de octubre. [Ref.ID 103199]
Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]
Actualizar mis citas con la selección